Pharmacyclics Announces Date of Second Quarter Fiscal 2010 Financial Results and Conference Call
SUNNYVALE, Calif., Feb. 8 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that it will report financial results for the second fiscal quarter ended December 31, 2009 after the NASDAQ Market closes on Thursday February 11, 2010. The company will conduct a conference call and an audio webcast at 1:30 p.m. PT on the same day. There will be a short slide presentation accompanying the webcast that can be found by clicking the link below.
Second Fiscal Quarter 2010 Conference Call and Webcast Details |
||||
Date: |
February 11, 2010 |
|||
Time: |
1:30 PM PT |
|||
Toll-free: |
+1-866-727-3220 |
|||
International: |
+1-706-643-1591 |
|||
Conference ID: |
55218310 |
|||
Listen via Internet and view slides: http://ir.pharmacyclics.com/events.cfm |
||||
A webcast replay will be available on the Pharmacyclics website for 30 days.
About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The Company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics' business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding to their product pipelines. Pharmacyclics strives to generate collaborations that allow it to retain valuable territorial rights and simultaneously fast forward the clinical development and commercialization of its products. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.
Contact: |
|
Ramses Erdtmann |
|
Vice President of Finance |
|
Phone: 408-215-3325 |
|
SOURCE Pharmacyclics, Inc.
Share this article